ER-α36, a Variant of ER-α, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the MAPK/ERK and PI3K/Akt Pathways

• DOI: 10.1371/journal.pone.0009013
• Publication Date: 2010-02-01T23:52:57Z
• Authors: Sheng-Li Lin; Li-Ying Yan; Xin-Tian Zhang; Ju Yuan; Mo Li; Jie Qiao; Zhao-Yi Wang; Qing-Yuan Sun
• Keywords: Estrogen receptor alpha; Antiestrogen; Fulvestrant

Recently, a novel variant of ER-alpha, ER-alpha36 was identified and cloned. lacks intrinsic transcription activity mainly mediates nongenomic estrogen signaling. Here, we studied the role signaling pathways mediated by in tamoxifen resistance agonist action.The cellular localization examined immunofluorescence MCF-7 cells Hec1A cells. breast cancer cells, expressing recombinant (MCF-7/ER36), endometrial with siRNA knockdown (Hec1A/RNAiER36) were treated 17beta-estradial (E2) (TAM) absence presence kinase inhibitor U0126 LY294002. We phosphorylation molecules expression c-Myc immunoblotting, tumor cell growth MTT assay.ER enhances TAM through activation membrane-initiated cancer, that is involved de novo acquired cancer.